Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: Ovarian Cancer
November 17, 2020Avastin has become the drug of choice for the maintenance treatment of ovarian cancer patients who do not have a BRCA mutation. However, upcoming patent expiries and expected competition from label expansions for the poly (ADP-ribose) polymerase (PARP) inhibitors and late-phase pipeline drugs will challenge Avastin’s position in the ovarian cancer market.
The PARP inhibitor Lynparza has quickly become the standard of care first-line maintenance therapy for patients with BRCA mutated ovarian cancer in the US and EU. However, the PARP inhibitors Zejula and veliparib will soon compete with Lynparza in this treatment setting. Although all three PARP inhibitors have also demonstrated an advantage over chemotherapy in patients without a BRCA mutation or a homologous recombination deficiency (HRD), the primary benefit was derived in patients with BRCA or other HRD mutations, which may limit uptake in the broader patient population.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Ovarian Cancer|